For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Research and development | 7,935,680 | 6,819,083.5* | 9,357,444 | 14,337,753 |
| General and administrative | 4,738,686 | 4,081,793* | 3,907,090 | 3,906,172 |
| Change in estimate for legal contingencies | - | 0* | - | - |
| Change in estimate for legal contingency | - | - | 0 | - |
| Income from insurance recovery | - | 0* | - | - |
| Total operating expenses | 12,674,366 | 10,900,876.5 | 13,264,534 | 18,243,925 |
| Operating loss | -12,674,366 | -10,900,876.5* | -13,264,534 | -18,243,925 |
| Interest expense | 2,199 | 0* | 0 | 0 |
| Interest and other income, net | 169,615 | 456,557* | 418,474 | 533,090 |
| Gain from asset sale | - | 89,605.5* | 91,400 | 89,363 |
| Other (income) expense | -2,411 | -502* | 0 | 0 |
| Total other (income) expense, net | 165,005 | 545,660.5* | 509,874 | 622,453 |
| Loss before income taxes | -12,509,361 | -10,355,216* | -12,754,660 | -17,621,472 |
| Provision for income taxes | 0 | 300* | 0 | 3,400 |
| Net loss | -12,509,361 | -10,355,516 | -12,754,660 | -17,624,872 |
| Basic EPS | -0.32 | -0.261 | -0.32 | -0.44 |
| Diluted EPS | -0.32 | -0.261 | -0.32 | -0.44 |
| Basic Average Shares | 39,681,465 | 39,662,799 | 39,665,927 | 39,659,266 |
| Diluted Average Shares | 39,681,465 | 39,662,799 | 39,665,927 | 39,659,266 |
Skye Bioscience, Inc. (SKYE)
Skye Bioscience, Inc. (SKYE)